FDA adds clinical pharmacology to growing pile of biosimilar guidances
This article was originally published in Scrip
Executive Summary
The US FDA has published another draft guidance on biosimilar product development, this time on clinical pharmacology studies, which the agency says will help companies design studies to show that there are no "clinically meaningful differences" between the biosimilar and its reference drug.